Total Payments
$997.08
2024 Payments
$269.90
Companies
9
Transactions
27
Medicare Patients
1,507
Medicare Billing
$2.3M
Payment Breakdown by Category
Food & Beverage$980.84 (98.4%)
Education$16.24 (1.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $980.84 | 26 | 98.4% |
| Education | $16.24 | 1 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $607.47 | 11 | $0 (2024) |
| Janssen Biotech, Inc. | $157.22 | 5 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $79.75 | 4 | $0 (2023) |
| Horizon Therapeutics plc | $41.50 | 2 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $30.93 | 1 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $26.35 | 1 | $0 (2023) |
| Amgen Inc. | $24.60 | 1 | $0 (2023) |
| Insmed, Inc. | $16.24 | 1 | $0 (2022) |
| NESTLE HEALTHCARE NUTRITION INC. | $13.02 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $269.90 | 5 | ABBVIE INC. ($237.82) |
| 2023 | $469.48 | 10 | ABBVIE INC. ($278.33) |
| 2022 | $230.18 | 11 | ABBVIE INC. ($91.32) |
| 2021 | $27.52 | 1 | Horizon Therapeutics plc ($27.52) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $105.97 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: Immunology | ||||||
| 09/24/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: IMMUNOLOGY | ||||||
| 08/01/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $6.86 | General |
| Category: IMMUNOLOGY | ||||||
| 03/29/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Immunology | ||||||
| 12/06/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $83.08 | General |
| Category: Immunology | ||||||
| 11/17/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $27.10 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: IMMUNOLOGY | ||||||
| 09/21/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $103.78 | General |
| Category: IMMUNOLOGY | ||||||
| 05/22/2023 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/14/2023 | NESTLE HEALTHCARE NUTRITION INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 03/02/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/28/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $30.93 | General |
| Category: INTERNAL MEDICINE | ||||||
| 01/12/2023 | Amgen Inc. | AVSOLA (Biological) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: Inflammation | ||||||
| 01/11/2023 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/13/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.78 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Immunology | ||||||
| 11/21/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Immunology | ||||||
| 11/08/2022 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $22.53 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/08/2022 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $24.83 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: IMMUNOLOGY | ||||||
| 10/11/2022 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/05/2022 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 08/23/2022 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: UPLIZNA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 52 | 7,858 | $894,545 | $153,169 |
| 2022 | 6 | 127 | 863 | $97,024 | $20,426 |
| 2021 | 20 | 635 | 27,766 | $2.9M | $520,723 |
| 2020 | 17 | 693 | 26,720 | $8.4M | $1.6M |
Total Patients
1,507
Total Services
63,207
Medicare Billing
$2.3M
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 13 | 6,300 | $428,400 | $110,506 | 25.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 11 | 1,505 | $445,480 | $39,161 | 8.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 14 | 31 | $17,453 | $2,595 | 14.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 22 | $3,212 | $908.42 | 28.3% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 11 | 690 | $69,064 | $14,750 | 21.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 32 | 57 | $14,250 | $2,561 | 18.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 14 | 16 | $6,500 | $1,500 | 23.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 46 | 72 | $3,600 | $657.51 | 18.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 11 | $1,485 | $618.04 | 41.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 13 | 17 | $2,125 | $339.51 | 16.0% |
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2021 | 17 | 1,700 | $801,504 | $171,240 | 21.4% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2021 | 12 | 1,885 | $444,395 | $65,144 | 14.7% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2021 | 19 | 2,085 | $282,351 | $61,968 | 21.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 58 | 3,480 | $254,527 | $54,473 | 21.4% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2021 | 12 | 875 | $148,120 | $35,970 | 24.3% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2021 | 16 | 4,830 | $151,131 | $34,724 | 23.0% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2021 | 16 | 820 | $344,736 | $27,302 | 7.9% |
| J0485 | Injection, belatacept, 1 mg | Office | 2021 | 12 | 9,675 | $112,448 | $25,051 | 22.3% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2021 | 11 | 1,650 | $216,035 | $23,042 | 10.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 125 | 187 | $46,750 | $9,053 | 19.4% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 24 | 25 | $6,250 | $2,261 | 36.2% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 137 | 235 | $11,750 | $2,257 | 19.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis | Office | 2021 | 32 | 136 | $17,000 | $2,058 | 12.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 38 | 38 | $5,130 | $1,914 | 37.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 24 | 24 | $5,880 | $1,658 | 28.2% |
About Tara Bell, NP
Tara Bell, NP is a Nurse Practitioner healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/23/2012. The National Provider Identifier (NPI) number assigned to this provider is 1487909826.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Tara Bell, NP has received a total of $997.08 in payments from pharmaceutical and medical device companies, with $269.90 received in 2024. These payments were reported across 27 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($980.84).
As a Medicare-enrolled provider, Bell has provided services to 1,507 Medicare beneficiaries, totaling 63,207 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Nurse Practitioner
- Location Rochester, MN
- Active Since 07/23/2012
- Last Updated 10/01/2012
- Taxonomy Code 363L00000X
- Entity Type Individual
- NPI Number 1487909826
Products in Payments
- SKYRIZI (Biological) $402.35
- RINVOQ (Biological) $182.66
- STELARA (Biological) $99.45
- SAPHNELO (Biological) $79.75
- REMICADE (Biological) $42.06
- ENTYVIO (Biological) $30.93
- KRYSTEXXA (Biological) $27.52
- DUPIXENT (Biological) $26.35
- AVSOLA (Biological) $24.60
- LINZESS (Drug) $22.46
- Arikayce (Drug) $16.24
- TREMFYA (Drug) $15.71
- UPLIZNA (Drug) $13.98
- ZENPEP (Drug) $13.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nurse Practitioner Doctors in Rochester
Dr. Grace Wlasowicz, Rn, Phd, Npp, RN, PHD, NPP
Nurse Practitioner — Payments: $41,479
Nurse Practitioner $41,479
Jamie Carroll, Aprn, APRN
Nurse Practitioner — Payments: $15,059
Nurse Practitioner $15,059
Elizabeth Nafornita, Fnp-C, FNP-C
Nurse Practitioner — Payments: $13,692
Nurse Practitioner $13,692
Brooke Sukalski, Np, NP
Nurse Practitioner — Payments: $12,198
Nurse Practitioner $12,198
Jamie Haraden, Rn, Msn, RN, MSN
Nurse Practitioner — Payments: $12,169
Nurse Practitioner $12,169
Julie Socha, N.p, N.P
Nurse Practitioner — Payments: $10,464
Nurse Practitioner $10,464